loading page

The Role of DNAJB9 in the Pathogenesis of Triple Negative Breast Cancer: Case Report
  • +2
  • Puneet Razdan,
  • Shannon Wills,
  • Priya Razdan,
  • Dawn Severson,
  • Omokayode Osobamiro
Puneet Razdan
Michigan State University

Corresponding Author:[email protected]

Author Profile
Shannon Wills
Henry Ford Macomb Hospital
Author Profile
Priya Razdan
Oakland University William Beaumont School of Medicine
Author Profile
Dawn Severson
Henry Ford Macomb Hospital
Author Profile
Omokayode Osobamiro
Henry Ford Macomb Hospital
Author Profile

Abstract

Background Triple negative breast cancer (TNBC) has been increasing in incidence over the last 20 years, with reports of 2,088,849 cases of TNBC in 2018 (2). Given its lack of treatment options, high recurrence rate, and poor prognosis, there is a need to find new methods to help drive treatment options for these patients (3). A previous study showed a link between TNBC and a heat shock protein called DNAJB9, with elevated levels of DNAJB9 demonstrating inhibition of epithelial-mesenchymal transition of TNBC and thus protection against metastasis (1). Case In this case study, we present a patient with non-metastatic TNBC treated with neoadjuvant chemotherapy and resection who had a complete pathologic response after receiving less than the standard of care due to an adverse event. During her 3rd cycle of chemotherapy, she developed acute DNAJB9-related fibrillary glomerulonephritis. Conclusion This suggests that physiologically DNAJB9 may be upregulated in patients with TNBC for protection against transformation and metastasis. Therefore, it postulates that measuring the levels of DNAJB9 could potentially be used as a biomarker to determine the response of the body to TNBC, thus functioning as a prognostic indicator. Furthermore, pharmacologic treatments could be developed that upregulate this process and serve as a cancer specific therapy.